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Abstract
Background: Insulin-like growth factor-binding protein-7 (IGFBP7) is a secretory protein with a
molecular mass of approximately 30 kDa. It is abundantly expressed in the uterine endometrium
during the secretory phase of the menstrual cycle. Decreased IGFBP7 expression has been
observed in some cancers and leiomyomata.
Methods:  To determine whether serum IGFBP7 levels reflect changes in uterine IGFBP7
expression in humans during the menstrual cycle, and to examine whether serum IGFBP7 levels are
altered in patients with various disorders, we developed a novel, dual-antibody sandwich enzyme-
linked immunosorbent assay (ELISA). Firstly, concentrations of IGFBP7 released into the medium
were determined in cultured endometrial stromal and glandular cells. Blood samples were
collected from women who had normal menstrual cycles and who had been diagnosed with
endometriosis. Serum from hemodialysis patients and gastrointestinal cancers was also used to
determine the IGFBP7 levels.
Results: Using this new ELISA, we demonstrated that cultured uterine cells secrete IGFBP7 into
the medium. Patients with endometriosis and those with type II diabetes mellitus undergoing
hemodialysis had significantly higher serum concentrations of IGFBP7 than the relevant control
subjects. There were no differences in serum IGFBP7 levels in women at different stages of the
menstrual cycle. Furthermore, serum IGFBP7 levels in patients with colorectal, esophageal, or
endometrial cancer were not different than normal healthy subjects.
Conclusion: Our observations suggest that IGFBP7 is associated with the pathophysiology of
endometriosis and diabetes mellitus, and that serum IGFBP7 levels do not reflect enhanced uterine
expression of IGFBP7 mRNA during the menstrual cycle.
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Background
We are interested in factors that play a crucial role in the
establishment of pregnancy. Previously, we found that
IGFBP7 is highly expressed in the rat uterus during
implantation [1]. IGFBP7, also known as IGFBP-related
protein 1 (IGFBP-rP1), mac25, prostacyclin stimulating
factor (PSF), and angiomodulin [2], is a secreted glycopro-
tein of the IGFBP-rP family, which binds insulin and insu-
lin insulin-like growth factor I (IGF-I). However, unlike
IGFBPs 1–6, IGFBP7 has a relatively low affinity for IGF,
while its affinity for insulin is 500-fold higher [3]. At
present, the biological functions of IGFBP7 are unclear.
While it is expressed in a wide variety of human tissues,
including gut [4], it is notably abundant in female repro-
ductive organs such as the mature follicle [5], the corpus
luteum [6], and the uterus [7,8]. IGFBP7 is present in uter-
ine glandular epithelial cells and stromal cells, particu-
larly during the secretory phase of the menstrual cycle,
and IGFBP7 mRNA levels in late secretory stage are
approximately 150-fold higher than in the proliferative
stage [7]. Finally, uterine leiomyomata express lower lev-
els of IGFBP7 than the adjacent myometrium [9].
High grade invasive breast cancers lack IGFBP7 expression
[10,11], which suggests that IGFBP7 may be associated
with tumorigenesis. Patients with low IGFBP7 expression
levels had reduced survival as compared to patients with
higher expression levels [12]. In fact, the gene encoding
IGFBP7 was originally identified on the basis of its
reduced mRNA expression levels in meningioma cell lines
relative to normal cells [13]. In addition, recombinant
IGFBP7 suppresses the growth of cultured human tumor
cells through a mechanism that involves an increase in the
number of cells in the G1 phase of the cell cycle [14].
Here, we report the development of an ELISA for measur-
ing serum IGFBP7. Our objective was to test the hypothe-
sis that circulating IGFBP7 levels reflect localized changes
IGFBP7 expression, particularly in the uterus, in which
there is a marked increase in IGFBP7 expression during
the secretory phase of the menstrual cycle, and in solid
tumors, in which there is reduced expression of IGFBP7.
We examined whether changes in uterine IGFBP7 expres-
sion during the menstrual cycle correlated with serum
IGFBP7 levels. Given the association between IGFBP7 and
disease, we also compared serum IGFBP7 levels in
patients with endometriosis or endometrial, colorectal or
esophageal cancer to normal healthy individuals. Lastly,
we examined serum IGFBP7 levels in patients undergoing
hemodialysis, many of whom had type II diabetes melli-
tus. We found that circulating levels of IGFBP7 are
enhanced in patients with endometriosis and type II dia-
betes. However, peripheral blood levels of IGFBP7 did not
correlate with increased IGFBP7 expression in the uterus
during the secretory phase of the menstrual cycle.
Methods
Preparation of subconfluent uterine cells and blood 
collection
Endometrial stromal cells (ESCs) from the proliferative
phase of the menstrual cycle were prepared as described
previously [8]. ESCs were determined to be at the prolifer-
ative phase based on the patients' menstrual history,
serum estradiol and progesterone levels at the time of
sample collection, and histological examination using
standard histological criteria. The samples were collected
after obtaining informed consent from the patients in
accordance with the Helsinki Declaration and the require-
ments of the Clinical Research Ethics Committee of the
Tokyo Medical University Hospital (Shinjuku, Tokyo).
Cells were cultured in DMEM/F-12 medium (Invitrogen,
Carlsbad, CA, USA) containing 10% (v/v) charcoal-dex-
tran-treated fetal bovine serum (10% stripped FBS,
Hyclone, South Logan, UT, USA) and antibiotics (50 μg/
ml penicillin, 50 μg/ml streptomycin, 100 μg/ml neomy-
cin, 100 μg/ml gentamicin and 2.5 μg/ml fungizone, Inv-
itrogen). Subconfluent cells were cultured in 12-well
culture plates with DMEM/F-12 medium containing 2%
(v/v) stripped FBS and antibiotics. The IGFBP7-specific
siRNA (Darmacon Inc., Chicago, IL, USA) was used as pre-
viously described [8]. The glandular cell line EM1, which
was originally called EM-E6/E7/TERT-1(EM-1) [15], was
cultured in DMEM containing 10% (v/v) FBS (JRH Bio-
sciences, ACSL, Lenexa, MD) and antibiotics, as described
above. Blood samples were collected from 62 women
between the ages of 23 and 45 who had normal menstrual
cycles. The menstrual cycle stage of each subject was deter-
mined based on menstrual history and serum estradiol
and progesterone levels at the time of sample collection.
Blood samples were obtained from 11 women who had
been diagnosed with endometriosis, 33 men undergoing
hemodialysis, and 58 men requiring elective open surgery
for colorectal (n = 40) or esophageal cancers (n = 18). Of
the hemodialysis patients, 18 had been diagnosed with
type II diabetes mellitus. This study was performed
according to the Helsinki Declaration and was approved
by the Ethical Committee of Nippon Medical School Hos-
pital. Signed informed consent to participate in the study
was obtained from all patients prior to phlebotomy or
surgery.
IGFBP7 ELISA
IGFBP7 levels in culture media and serum were measured
using a novel sandwich ELISA, which incorporated a pol-
yclonal and a monoclonal anti-IGFBP7 antibody (R&D
Systems Inc.). The polyclonal anti-IGFBP7 antibody was
diluted to 1 μg/ml in PBS and incubated overnight at
room temperature (R/T) in poly-L-lysine-coated 96-well
microtiter plates. The wells were washed with PBS con-
taining 0.1% Tween-20 (PBST), blocked with 3% (w/v)
BSA in PBS at R/T for 1 hour (h), and then washed againReproductive Biology and Endocrinology 2008, 6:54 http://www.rbej.com/content/6/1/54
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with PBST, after which samples diluted with PBS contain-
ing 0.1% (w/v) BSA(PBSB) were added. Recombinant
human IGFBP7 (R&D Systems Inc.) at concentrations of
0.24, 0.97, 3.9, 15.6, or 62.5 ng/ml in PBSB was also
added as a standard. Plates were incubated for 2 h at R/T,
and then the wells were washed with PBST. Monoclonal
anti-IGFBP7 antibody (1 μg/ml) in PBSB was then added.
After another period of incubation for 2 h at R/T, the
plates were washed with PBST, incubated for 1 h at R/T
with 1 μg/ml peroxidase-conjugated goat anti-mouse IgG
antibody (Vector Lab. Inc.), and then washed again with
PBST. A substrate reagent (100 μl) (R&D Systems Inc.)
was added to the wells, and the chromogenic reaction was
allowed to proceed for 10 minutes at R/T, at which point
50 μl of 2 N HCl was added to each well to stop the reac-
tion. The plate was read at 450 nm in a microtiter plate
reader (SAFIRE, Wako Pure Chemical, Osaka, Japan).
Inter- and intra-assay coefficients of variation were 19.9%
and 14.0%, respectively. The average percent recovery was
approximately 100%. The sensitivity of the assay was 0.3
ng/mL.
Statistics
Results are presented as means ± standard error (SE), and
differences were analyzed using the Student t test or
ANOVA test. A P value of less than 0.05 was considered to
be statistically significant.
Results
We developed a novel IGFBP7 ELISA using two anti-
IGFBP7 antibodies, as described in Materials and Meth-
ods. The standard curve generated with recombinant
IGFBP7 was linear between 0.3 and 20 ng/ml (Fig. 1A).
We recently demonstrated that IGFBP7 is expressed in the
human uterus, and that IGFBP7 mRNA levels are up-regu-
lated in ESCs and glandular epithelial cells during the
receptive phase of the menstrual cycle [8]. We first deter-
mined whether cultured primary ESCs and EM1 glandular
epithelial cells (GE cells) secreted IGFBP7. IGFBP7 gradu-
ally accumulated in the culture medium of ESCs and GE
cells over a 24 h period of incubation, reaching levels of
55 and 25 ng/ml, respectively, at 24 h (Fig. 1B). When
ESCs were treated with IGFBP7 siRNA to knock-down the
expression of IGFBP7, the protein levels of IGFBP7 were
reduced by 86% (approximately 7.5 ng/mL). These results
confirmed that cultured ESCs secrete IGFBP7, and demon-
strated that ESCs secrete about 2-fold more IGFBP7 than
GE cells.
There are marked changes in uterine IGFBP7 mRNA levels
during the menstrual cycle. To determine if these changes
are reflected in serum IGFBP7 levels, we measured IGFBP7
concentrations in sera from 62 women at different phases
of the menstrual cycle (Fig. 2A). Serum IGFBP7 levels did
not change significantly throughout the menstrual cycle.
The average IGFBP7 level in serum was 33 ± 13.1 ng/ml
(median of 35 ng/ml). We also observed that mean serum
IGFBP7 levels do not differ between males and females
(data not shown).
Analysis of serum IGFBP7 levels in patients with endome-
triosis revealed that these patients had significantly higher
average levels of IGFBP7 than control subjects (Fig. 2B).
For this study, the 62 female subjects with normal men-
strual cycles that were analyzed in Fig. 1 served as control
subjects. Based on a previous report by López-Bermejo et
al. [16] showing an association of serum IGFBP7 with
insulin resistance, we examined the levels of IGFBP7 in
Determination of IGFBP7 protein levels in conditioned media  from human ESCs and GE cells Figure 1
Determination of IGFBP7 protein levels in condi-
tioned media from human ESCs and GE cells. The 
conditioned media of subconfluent cells was collected at the 
indicated times and stored frozen until use. (A) Representa-
tive standard curve obtained by ELISA using recombinant 
human IGFBP7 in PBS containing 0.1% BSA. Data represents 
the means of four replicates. (B) IGFBP7 levels in conditioned 
media over time. The conditioned medium of GE cells was 
measured at the 24 h time point only. Gray column; IGFBP7 
levels in the medium of ESCs treated for 24 h with IGFBP7 
siRNA (10 pmol). The data represents the means ± SE of 
three separate cultures, assayed in duplicate.
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non-diabetic and diabetic patients receiving hemodialy-
sis. Patients with type II diabetes mellitus (DM) had sig-
nificantly higher IGFBP7 levels than non-DM patients
(Fig. 3). Analysis of serum IGFBP7 levels of patients with
endometrial, colon or esophageal cancer revealed that
IGFBP7 levels did not differ significantly from those of
control subjects (Fig. 4).
Discussion
Endometriosis, which is defined as the presence and pro-
liferation of endometrial glands and stroma outside the
uterine cavity, is one of the most common benign gyneco-
logical diseases in women of reproductive age [17]. The
disease is estrogen dependent and is most often treated
using gonadotropin-releasing hormone (GnRH) agonists,
with the aim of downregulating ovarian estrogen produc-
tion. We found that women with endometriosis had sig-
nificantly higher serum IGFBP7 levels than normal
women. The pathophysiological mechanism underlying
endometriosis remains unclear but may involve a dys-
Serum IGFBP7 levels in patients at different phases of the  menstrual cycle (A) and with endometriosis (B) Figure 2
Serum IGFBP7 levels in patients at different phases 
of the menstrual cycle (A) and with endometriosis 
(B). (A) The sera from 62 women with regular menstrual 
cycles were tested. The numbers in parentheses indicate the 
number of subjects at each stage. (B) The sera from 11 
patients with endometriosis were tested along with those of 
the 62 women with regular menstrual cycles, described for 
A, who served as controls for this study (Control). Data rep-
resents the means ± SE. *P < 0.05 as compared to Control.
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Serum IGFBP7 levels in hemodialysis patients with or without  type II diabetes (DM) Figure 3
Serum IGFBP7 levels in hemodialysis patients with 
or without type II diabetes (DM). Serum from 33 hemo-
dialysis patients without DM (15 subjects) and with DM (18 
patients) was collected. *P < 0.05 as compared to without 
DM (Control).
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Serum IGFBP7 levels in patients with endometrial cancer  (Endo), colon cancer (Col) or esophageal cancer (Eso) Figure 4
Serum IGFBP7 levels in patients with endometrial 
cancer (Endo), colon cancer (Col) or esophageal can-
cer (Eso). Serum was collected from each patient (5 Endo, 
40 Col, 18 Eso) before operation.
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function of the immune system. It is believed that during
the development of endometriosis, immune cells (mainly
macrophages) are recruited into the peritoneal cavity,
where they engage in phagocytosis of retrograde endome-
trial debris [18]. Peritoneal macrophages contribute to the
progression of endometriosis by producing a variety of
soluble inflammatory mediators [19,20]. Supporting this
scenario is that subjects with endometriosis have signifi-
cantly higher serum levels of interleukin (IL)-6, monocyte
chemotactic protein-1, and interferon-gamma as com-
pared to control women [21]. Significantly, IL-6 has been
shown to be a possible nonsurgical marker for predicting
the development of endometriosis [22]. IGFBP7 expres-
sion has been shown to be up-regulated in prostate cells
by transforming growth factor (TGF)-β, IGF-I, and retinoic
acid [23], and in osteoblasts by cortisol [24]. It is possible
that the increased serum IGFBP7 levels seen in patients
with endometriosis reflect inflammation in the pelvic cav-
ity and the production of various cytokines, which can ele-
vate IGFBP7 production.
Various lines of evidence suggest that IGFBP7 inhibits
tumor progression [10-14,25]. Immunohistochemical
analysis revealed that while normal breast tissues show
strong IGFBP7 expression, invasive breast cancer tissues
do not express IGFBP7 [26]. On the contrary, IGFBP7 has
also been identified as a gene that is up-regulated in
inflammatory breast cancer (IBC) [27]. IBC is a unique
type of invasive breast cancer which progresses aggres-
sively with the extensive erythema and edema, and dim-
pling of the skin. Up-regulation of IGFBP7 in IBC seems
to contradict the above reports [10-14,25], which is that
IGFBP7 inhibits tumor progression. Although the molec-
ular association of IGFBP7 with tumorigenesis are still
unknown, this factor might be related to angiogenesis
and/or inflammation, because IGFBP7 is an endothelial
marker that is expressed at higher levels in the vasculature
of malignant tissues than in normal endothelial cells [28].
There is some suggestion that the gene for IGFBP7 may be
silenced by promoter hypermethylation. Regional DNA
hypermethylation of CpG islands commonly promotes
tumor progression by silencing the expression of tumor
suppressor genes [29]. Komatsu et al. [30] found an
inverse relationship between the degree of DNA methyla-
tion associated with hepatocarcinogenesis and the expres-
sion levels of IGFBP7. However, despite these strong links
between IGFBP7 and tumorigenesis, we did not observe a
relationship between serum IGFBP7 and three different
types of cancer. It is possible that local changes in IGFBP7
are not reflected in IGFBP7 levels in the peripheral blood,
at least with regard to cancer. Previously, analysis using
immunohistochemical staining [4] revealed intense
IGFBP7-positive staining in the epithelia of distal tubules
of the breast, bronchus, and kidney, and peripheral nerve
fibers and glial cells of the cerebellum. The adrenal gland,
with the exception of the area of zona fasciculate, also
exhibited intense staining. Most endothelial cells were
positive for IGFBP7, whereas fat cells, plasma cells, and
lymphocytes were negative. Thus, IGFBP7 appears to be
ubiquitously expressed in many organs, and could poten-
tially be released from many sources into circulation. This
may be one of the reasons why we could not detect local
changes in IGFBP7 by measuring serum levels of IGFBP7.
Because IGFBP7 binds to the extracellular matrix (ECM)
components type IV collagen and heparin sulfate prote-
oglycan [2,3], most uterine IGFBP7 might be trapped in
the ECM surrounding the endometrial cells. In addition,
we previously demonstrated that intracellular IGFBP7,
not secreted IGFBP7, is important for uterine decidualiza-
tion [8]. Since high level expression of IGFBP7 was also
found in blood vessels of the endometrium [8], IGFBP7
might effect vascular function in the endometrium. Thus,
changes in IGFBP7 expression associated with uterine
physiology might not be reflected in serum levels. Identi-
fying the potential source of changes in serum IGFBP7
under pathological conditions might prove to be difficult.
Hemodialysis patients with diabetes had significantly
higher serum IGFBP7 levels than hemodialysis patients
without diabetes. This result seems to be partially consist-
ent with a previous report [16], in which circulating
IGFBP7 levels in non-diabetic men correlated negatively
with serum adiponectin levels, and positively with serum
C-reactive protein (CRP) and soluble tumor necrosis fac-
tor receptor 2 (sTNFR2) levels, indicating that IGFBP7 is
associated with insulin resistance. IGFBP7 inhibits the
binding of insulin to its receptor and decreases tyrosine
phosphorylation of the insulin receptor and insulin-
receptor substrate I [31]. Serum levels of IGFBP7 were
clearly higher in both non-diabetic and diabetic hemodi-
alysis patients as compared to other conditions. While our
results do not provide an explanation for this for this dif-
ference, it is possible that hemodialysis triggers IGFBP7
release. However, since insulin resistance is also evident in
non-diabetic dialysis patients [32], the increase in serum
IGFBP7 levels might also be due to insulin resistance.
Regardless of the mechanism, the results of the current
study support the idea that IGFBP7 is associated with
insulin resistance in non-insulin dependent diabetes mel-
litus patients.
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